ALGS Q1 2023 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+5.9% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$24M-878.4% margin

Net Income

-$23M-843.0% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

-23.0%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$122M

Total Liabilities

$37M

Stockholders' Equity

$85M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	+5.9%
Gross Profit	$3M	$3M	+5.9%
Operating Income	-$24M	-$36M	+32.7%
Net Income	-$23M	-$36M	+35.5%